GleamWall
中文EN

PFSA Profusa, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1859807 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY23.0%
TTM EPS YoY197.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-155.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets73.0%
Debt / equity0.00x
Current ratio0.02x
Interest coverage-174.12x

Cash quality & payout

Operating cash flow / net income0.47x
Accruals ratio-82.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$0
R&D expense$222,000$823,000$1.15M$1.25M$722,000$393,000$434,000$259,000
SG&A expense$4.63M$1.72M$2.86M$2.31M$20.99M$610,000$990,000$823,000
Operating income-$4.85M-$2.54M-$4.01M-$3.57M-$21.71M-$1.00M-$1.42M-$1.08M
Interest expense$22,000$21,000$18,000$25,000$169,000$1.19M$1.14M$1.29M
Pretax income—————-$8.19M-$1.10M-$7.57M
Income tax—————$2,386$19,352$16,534
Net income-$4.95M-$8.76M-$3.46M-$8.57M-$26.09M-$2.35M-$2.72M-$2.25M
EBITDA-$4.85M———————
EPS (basic)-6.23-151.80-2.05—-6,167.85-9,100.78-105.09—
EPS (diluted)-6.23-151.80-2.05—-6,167.85-9,100.78-105.09—
Weighted avg. shares (diluted)794,92057,6761.69M—4,23025825,844—
Banking
Deposits—————$29,171$13,162—
Balance sheet
Cash & equivalents$339,000$719,000$375,000$1.78M$3.01M$39,000$19,000$191,000
Current assets$394,000$841,000$662,000$3.76M$4.20M$687,867$63,183$260,000
PP&E, net$80,000$84,000$13,000$8,000————
Total assets$28.89M$1.04M$862,000$3.77M$4.25M$1.96M$1.98M$3.07M
Current liabilities$21.09M$28.17M$29.02M$22.26M$23.54M$16.18M$13.25M$57.13M
Total liabilities$21.09M$28.17M$29.06M$30.43M$38.21M$23.14M$14.30M$57.13M
Shareholders' equity$7.79M-$27.13M-$28.20M-$26.66M-$33.91M-$124.18M-$121.92M-$119.20M
Shares outstanding2.52M132,3082.38M12,32041.73M5.19M5.19M25,844
Cash flow statement
Operating cash flow-$1.68M-$2.63M-$2.58M-$5.13M-$10.62M-$589,000-$537,000-$238,000
Capital expenditure$1,000$73,000$5,000—————
Free cash flow-$1.68M-$2.71M-$2.58M—————
Investing cash flow-$1,000-$73,000$1.15M-$1.01M-$7.49M-$1$6.49M$457,936
Financing cash flow$1.30M$3.05M$28,000$4.91M$20.94M$609,000$365,000$289,000
Depreciation & amortization$5,000———————
Stock-based compensation$126,000$188,000$187,000$187,000$617,000$82,000$5,000$5,000
Share buybacks—————$0$6.51M$595,439

Free plan shows the latest 8 periods; Pro shows all 21 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.